Global Chagas Disease Management Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2015 to 2020 and Forecast 2021 to 2027

$ PRICE - $ 3,000.00$ 8,900.00

Global Chagas Disease Management Market: By Treatment Type (Antiparasitic treatment, Symptomatic treatment), By Drug Type (Benznidazole, Nifurtimox), By Distribution Channel (Hospital pharmacies, Retail pharmacies, Online Pharmacies), and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

Global Chagas Disease Management Market was valued at US$ 5.72 Mn in 2020 and is expected to witness a CAGR of 7.6% over the forecast period 2021-2027. Chagas disease or American trypanosomiasis is a tropical parasitic disease caused by Trypanosoma cruzi. Chagas disease is transmitted by kissing bugs or triatomine bugs. Chagas disease can also transmit through blood transfusions, mother to foetus during pregnancy, and sometimes it causes through organ transplantation. The symptoms of the Chagas disease in early stage include swollen lymph nodes, fever, headache, and local swelling at the site of the bite. The chronic symptoms will appear after 8-12 weeks that may include expansion of ventricles leads to the heart failure, oesophagus or colon may cause death. The diagnosis of Chagas disease is complicated, require laboratory analysis of blood samples for the detection of antibodies against the Trypanosome cruzi. The Chagas disease is majorly present in the Latin America and spreading to North America and Europe region. Increase in the Chagas disease population in Latin America region, rise in the prevalence of Chagas disease due to unhygienic conditions might fuel the growth of Chagas disease management market over the forecast period. In addition, increase in the research and development of new products are one of the main factors that drive the growth of chagas disease management market. However, lack of awareness regarding the chagas disease treatment, a limited number of approved products in the current market, and supply chain issues with chagas disease drugs will hamper the growth of the chagas disease management market over the forecast period. In March 2017, Daiichi Sankyo Company Limited and Drugs for Neglected Diseases initiative (DNDi) are collaborated to form a joint research with regard to a new research program, the hit-to-lead project to develop the drugs for Chagas disease and leishmaniasis

 


Global Chagas Disease Management Market

MARKET SUMMARY
-
7.6%
  • Study Period– 2021-2027
  • Base Year– 2020
  • CAGR– 7.6%
  • Largest Market– Latin America
  • Fastest Growing Market–North America

Chagas Disease Management Market

  • The Chagas disease management market is divided into three categories: treatment, medicine, and distribution channel.
  • Chagas disease management market is still in the budding stage. Currently, very few players are actively involved in the development of new products for the Chagas disease treatment. Currently, there are only two drugs are available in the market for Chagas disease management namely, Benznidazole and Nifurtimox.
  • Several products are in pipeline that may enter the market near future.  Increase in research and developments for new products, acquisitions & mergers, collaborations and providing funds to various organizations for research and development activities might fuel the growth of Chagas disease management market.
  • For instance, in March 2012, Dundee University partnered with GSK, Wellcome Trust for neglected tropical disease research. In June 2012, Japan’s Astellas Pharma signed an agreement with the Drugs for Neglected Diseases initiative (DNDi) to collaborate on drug discovery research for three neglected tropical diseases: leishmaniasis, Chagas disease, and sleeping sickness.
  • Increase in the incidence Chagas disease in Latin America, and the unavailability of adequate treatment, spell opportunities for pharmaceutical companies across the region to develop new and improved diagnosis and treatment methods over the forecast period.
Market Key Players
  • AstraZeneca
  • Bayer AG
  • Daiichi Sankyo Company Ltd
  • Eisai Co Ltd
  • GlaxoSmithKline Plc.
  • Grupo Praxis Pharmaceutical SA
  • KaloBios Pharmaceuticals
  • Kancera AB
  • Novartis AG
  • Laboratorio Elea S
  • Oblita Therapeutics BVBA
  • Sanofi
Drivers and Restrains

Chagas Disease Management Market

Benznidazole is a vital antiparasitic medication used to treat Chagas disease. The Argentinian National Administration for Drugs, Food, and Medical Technologies (ANMAT) approved benznidazole, a medication developed by Laboratorio Elea Phoenix SA, for paediatric use in the treatment of Chagas disease in April 2018. Argentina now has the highest number of people infected with the Chagas disease. According to data given by Mundo Sano (an Argentine non-governmental organisation), over 7,300,000 people in Argentina were exposed to Chagas disease in 2017, with about 1,600,000 becoming infected. As a result, new drug approvals are projected to drive market growth in the near future.The approval of medications to treat Chagas disease is projected to drive the Chagas Disease Management Market’s growth in the near future. The campaign aims to raise public awareness about Chagas disease, which is still widespread in Latin American countries and affects around 6 million people worldwide. The World Health Organization (WHO) initiated a programme in 2007 to raise Chagas disease treatment rates and eradicate the disease. Bayer HealthCare, which makes the drug nifurtimox, which is used to treat Chagas disease, contributed to this WHO initiative. From 2012 through 2017, Bayer is expected to distribute 5 million tablets free of charge, according to the deal. In the foreseeable future, such initiatives are projected to boost market expansion.


Latin-America Got Significant Share

Chagas Disease Management Market

Geographically, the Chagas disease management market segmented into the following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Chagas disease is dominant in Latin America region and nowadays it is developing in the rest of world owing to the population mobility from Latin America. According to World Health Organization (WHO), about 8 million people are suffering from Chagas disease in worldwide, and majority of the people living in Latin America region. In addition, about 10,000 people die every year with the Chagas disease. Less number of products available in the market for treatment, and poor diagnostic methods to detect in the Latin America region are the major challenges for the Chagas disease management market in Latin America region. North America and Europe are the key regions for Chagas disease management market owing to increase in the prevalence of Chagas disease according to CDC, approximately 300,000 people are suffering from the Chagas disease in the North America region.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Key Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2015 to 2020) and forecast (2021 to 2027)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Chagas Disease Management Market Segmentation


Location

GEOGRAPHY


Report

Table Of Content


Report

Company Profile

  • AstraZeneca (U.K)
  • Bayer AG (Germany)
  • Daiichi Sankyo Company Ltd (Japan)
  • Eisai Co Ltd (Japan)
  • GlaxoSmithKline Plc. (U.K)
  • Grupo Praxis Pharmaceutical SA (Spain)
  • KaloBios Pharmaceuticals, Inc. (U.S.)
  • Kancera AB (Sweden)
  • Novartis AG (Switzerland)
  • Laboratorio Elea S.A.C.I.F. y A (Argentina)
  • Oblita Therapeutics BVBA (Belgium)
  • Sanofi (France)

Description

Global Chagas Disease Management Market was valued at US$ 5.72 Mn in 2020 and is expected to witness a CAGR of 7.6% over the forecast period 2021-2027. Chagas disease or American trypanosomiasis is a tropical parasitic disease caused by Trypanosoma cruzi. Chagas disease is transmitted by kissing bugs or triatomine bugs. Chagas disease can also transmit through blood transfusions, mother to foetus during pregnancy, and sometimes it causes through organ transplantation. The symptoms of the Chagas disease in early stage include swollen lymph nodes, fever, headache, and local swelling at the site of the bite. The chronic symptoms will appear after 8-12 weeks that may include expansion of ventricles leads to the heart failure, oesophagus or colon may cause death. The diagnosis of Chagas disease is complicated, require laboratory analysis of blood samples for the detection of antibodies against the Trypanosome cruzi. The Chagas disease is majorly present in the Latin America and spreading to North America and Europe region. Increase in the Chagas disease population in Latin America region, rise in the prevalence of Chagas disease due to unhygienic conditions might fuel the growth of Chagas disease management market over the forecast period. In addition, increase in the research and development of new products are one of the main factors that drive the growth of chagas disease management market. However, lack of awareness regarding the chagas disease treatment, a limited number of approved products in the current market, and supply chain issues with chagas disease drugs will hamper the growth of the chagas disease management market over the forecast period. In March 2017, Daiichi Sankyo Company Limited and Drugs for Neglected Diseases initiative (DNDi) are collaborated to form a joint research with regard to a new research program, the hit-to-lead project to develop the drugs for Chagas disease and leishmaniasis

 

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX